Does celecoxib have a role in the treatment of patients with colorectal cancer?

Clinical Colorectal Cancer

Volumn 8, Issue 1, 2009, Pages 11-14

  Fakih, Marwan G ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5 fluorouracil; Capecitabine; Gastrointestinal toxicity; Irinotecan; Oxaliplatin

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; FOLINIC ACID; GENE PRODUCT; INDOMETACIN; IRINOTECAN; N,N' BIS[7 (3 CHLOROANILINOSULFONYL) 1,2,3,4 TETRAHYDRO 1 ISOQUINOLYL]DISULFONYLIMIDE; OXALIPLATIN; PLACEBO; PROSTAGLANDIN E2; THROMBOXANE A2;

ADD ON THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME INHIBITION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAIR LOSS; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROSTAGLANDIN SYNTHESIS; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 61349196138     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.002     Document Type: Review

References (26)

1. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovo-rin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51.
2. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 2007; 25(18 suppl):165s (Abstract 4007).
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluo-rouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [published erratum in: Lancet 2000; 355:1372]. Lancet 2000; 355:1041-7.
4. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluo-rouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
5. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxali-platin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study [published erratum in: J Clin Oncol 2008; 26:3110]. J Clin Oncol 2008; 26:2013-9.
6. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
7. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000; 37:431-502.
8. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum in: Cell 1998; 94:following 271]. Cell 1998; 93:705-16.
9. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996; 25:773-91.
10. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinote-can-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16:2745-51.
11. Sakai H, Sato T, Hamada N, et al. Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon. J Physiol 1997; 505:133-44.
12. Sakai H, Diener M, Gartmann V, et al. Eicosanoid-mediated Cl- secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn Schmiedebergs Arch Pharmacol 1995; 351:309-14.
13. Giardiello FM, Spannhake EW, Du Bois RN, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous pol-yposis. Dig Dis Sci 1998; 43:311-6.
14. Nüsing RM, Reinalter SC, Peters M, et al. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 2001; 70:384-90.
15. Van Huyen JP, Bloch F, Attar A, et al. Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11). Dig Dis Sci 1998; 43:2649-51.
16. Ikuno N, Soda H, Watanabe M, et al. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87:1876-83.
17. Cao S, Black JD, Troutt AB, et al. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 1998; 58:3270-4.
18. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62:5778-84.
19. Javle MM, Cao S, Durrani FA, et al. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res 2007; 13:965-71.
20. Blanke CD, Benson AB III, Dragovich T, et al. A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002; 21:127a (Abstract 505).
21. El-Rayes BF, Zalupski MM, Manza SG, et al. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 2008; 61:283-9.
22. Maiello E, Giuliani F, Gebbia V, et al. FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol 2006; 17(suppl 7): vii55-9.
23. Köhne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19:920-6.
24. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irino-tecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779-86.
25. André T, Tournigand C, Mineur L, et al. Phase II study of an optimized 5-fluoro-uracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 2007; 18:77-81.
26. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-- a GERCOR study. J Clin Oncol 2006; 24:394-400.